Findings

What do systematic reviews say?

7 questions · 7 findings · 5 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 4 · 57.1%Moderate 1 · 14.3%High 0 · 0%

Benefits and harms of CSF plus antibiotics vs antibiotics alone

Duration of grade IV neutropenia (lower values signify better outcomes) · people with chemotherapy‐induced febrile neutropenia

Benefits and harms of CSF plus antibiotics showed no clear difference in duration of grade IV neutropenia (lower values signify better… compared with antibiotics alone (low certainty).

1 finding from 1 review

Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia 2014 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 1135 participants
Low

175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel

Neutropenia · women with recurrent epithelial ovarian cancer

175 mg/m2 paclitaxel showed no clear difference in neutropenia compared with 250 mg/m2 paclitaxel (low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 1.14 [0.74, 1.74]
1 study · 330 participants
Low

Weekly paclitaxel vs three‐weekly paclitaxel

Neutropenia · women with recurrent epithelial ovarian cancer

Weekly paclitaxel may leads to lower neutropenia compared with three‐weekly paclitaxel (low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 0.51 [0.27, 0.95]
2 studies · 260 participants
Low

Anti‐EGFR therapy vs placebo or usual care

Neutropenia · glioblastoma in adults

Anti‐EGFR therapy showed no clear difference in neutropenia compared with placebo or standard of care (low certainty).

1 finding from 1 review

Anti‐epidermal growth factor receptor therapy for glioblastoma in adults 2020 · Cochrane Headline outcomes only
OR 1.29 [0.82, 2.03]
4 studies · 1146 participants
Low

135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel

Neutropenia ‐ not reported · women with recurrent epithelial ovarian cancer

The review found no eligible studies for this question.

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leuprorelin vs treosulfan

Grade 3 to 4 neutropenia · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer

1 finding from 1 review

Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin

Grade 3 to 4 neutropenia · first‐line treatment of ovarian cancer

Weekly paclitaxel plus carboplatin showed no clear difference in haematological adverse event: Grade 3/4 neutropenia compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).

1 finding from 1 review

Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 1.11 [0.86, 1.43]
4 studies · 3639 participants
Moderate